Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Mechanistic Insights of Phenobarbital-Mediated Activation of Human but Not Mouse Pregnane X Receptor.

Li L, Welch MA, Li Z, Mackowiak B, Heyward S, Swaan PW, Wang H.

Mol Pharmacol. 2019 Sep;96(3):345-354. doi: 10.1124/mol.119.116616. Epub 2019 Jul 10.

PMID:
31436536
2.

SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia.

Paul S, Rausch CR, Welch MA, Kantarjian HM, Jabbour EJ.

Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):471-479. doi: 10.1016/j.clml.2019.06.011. Epub 2019 Jul 3. Review.

PMID:
31307896
3.

SUMOylating Two Distinct Sites on the A-type Potassium Channel, Kv4.2, Increases Surface Expression and Decreases Current Amplitude.

Welch MA, Forster LA, Atlas SI, Baro DJ.

Front Mol Neurosci. 2019 May 31;12:144. doi: 10.3389/fnmol.2019.00144. eCollection 2019.

4.

Long-Term Diabetic Microenvironment Augments the Decay Rate of Capsaicin-Induced Currents in Mouse Dorsal Root Ganglion Neurons.

Chen X, Duan Y, Riley AM, Welch MA, White FA, Grant MB, Obukhov AG.

Molecules. 2019 Feb 21;24(4):775. doi: 10.3390/molecules24040775.

5.

Role of the Advanced Practice Provider in Clinical Trials: Contributions to the Management of Patients Receiving Inotuzumab Ozogamicin.

Welch MA, Ryan JC, Galinsky IA.

J Adv Pract Oncol. 2017 Sep-Oct;8(6):631-636. Epub 2017 Sep 1. Review. No abstract available.

6.

Molecular Modeling of Drug-Transporter Interactions-An International Transporter Consortium Perspective.

Schlessinger A, Welch MA, van Vlijmen H, Korzekwa K, Swaan PW, Matsson P.

Clin Pharmacol Ther. 2018 Nov;104(5):818-835. doi: 10.1002/cpt.1174. Epub 2018 Aug 30.

PMID:
29981151
7.

Molecular Basis of Metabolism-Mediated Conversion of PK11195 from an Antagonist to an Agonist of the Constitutive Androstane Receptor.

Mackowiak B, Li L, Welch MA, Li D, Jones JW, Heyward S, Kane MA, Swaan PW, Wang H.

Mol Pharmacol. 2017 Jul;92(1):75-87. doi: 10.1124/mol.117.108621. Epub 2017 Apr 25.

8.

Identification of novel MRP3 inhibitors based on computational models and validation using an in vitro membrane vesicle assay.

Ali I, Welch MA, Lu Y, Swaan PW, Brouwer KLR.

Eur J Pharm Sci. 2017 May 30;103:52-59. doi: 10.1016/j.ejps.2017.02.011. Epub 2017 Feb 24.

9.

SUMOylation of the Hyperpolarization-Activated Cyclic Nucleotide-Gated Channel 2 Increases Surface Expression and the Maximal Conductance of the Hyperpolarization-Activated Current.

Parker AR, Welch MA, Forster LA, Tasneem SM, Dubhashi JA, Baro DJ.

Front Mol Neurosci. 2017 Jan 12;9:168. doi: 10.3389/fnmol.2016.00168. eCollection 2016.

10.

Toward predicting drug-induced liver injury: parallel computational approaches to identify multidrug resistance protein 4 and bile salt export pump inhibitors.

Welch MA, Köck K, Urban TJ, Brouwer KL, Swaan PW.

Drug Metab Dispos. 2015 May;43(5):725-34. doi: 10.1124/dmd.114.062539. Epub 2015 Mar 3.

11.

Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine.

Jabbour E, Kantarjian H, O'Brien S, Kadia T, Malik A, Welch MA, Teng A, Cortes J, Ravandi F, Garcia-Manero G.

Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):592-6. doi: 10.1016/j.clml.2013.05.004. Epub 2013 Jun 20.

12.

Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner.

Cornelison M, Jabbour EJ, Welch MA.

J Support Oncol. 2012 Jan-Feb;10(1):14-24. doi: 10.1016/j.suponc.2011.08.001.

PMID:
22244674
13.

Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation.

Cornelison AM, Welch MA, Koller C, Jabbour E.

Clin Lymphoma Myeloma Leuk. 2011 Jun;11 Suppl 1:S111-3. doi: 10.1016/j.clml.2011.03.032. Epub 2011 Apr 28.

PMID:
22035739
14.
15.

Integrating occupational therapy services in a kindergarten curriculum: a look at the outcomes.

Bazyk S, Michaud P, Goodman G, Papp P, Hawkins E, Welch MA.

Am J Occup Ther. 2009 Mar-Apr;63(2):160-71.

PMID:
19432054
16.

Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.

Chaturvedi S, Zivin J, Breazna A, Amarenco P, Callahan A, Goldstein LB, Hennerici M, Sillesen H, Rudolph A, Welch MA; SPARCL Investigators.

Neurology. 2009 Feb 24;72(8):688-94. doi: 10.1212/01.wnl.0000327339.55844.1a. Epub 2008 Sep 3.

PMID:
18768917
17.

Nelarabine activity in acute biphenotypic leukemia.

Alvarado Y, Welch MA, Swords R, Bruzzi J, Schlette E, Giles FJ.

Leuk Res. 2007 Nov;31(11):1600-3. Epub 2007 May 18. No abstract available.

PMID:
17512588
18.

Cutaneous leukocytoclastic vasculitis in a patient with myelodysplastic syndrome after therapy with the rapamycin analogue everolimus: case report and review of the literature.

Yee KW, Hymes SR, Heller L, Prieto VG, Welch MA, Giles FJ.

Leuk Lymphoma. 2006 May;47(5):926-9. No abstract available.

PMID:
16753882
19.

Cocaine-induced inhibition of process outgrowth in locus coeruleus neurons: role of gestational exposure period and offspring sex.

Snow DM, Carman HM, Smith JD, Booze RM, Welch MA, Mactutus CF.

Int J Dev Neurosci. 2004 Aug-Oct;22(5-6):297-308.

PMID:
15380829
20.

Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia.

Ault P, Kantarjian H, Welch MA, Giles F, Rios MB, Cortes J.

Leuk Res. 2004 Jun;28(6):613-8.

PMID:
15120938
21.

Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study.

Amarenco P, Bogousslavsky J, Callahan AS, Goldstein L, Hennerici M, Sillsen H, Welch MA, Zivin J; SPARCL Investigators.

Cerebrovasc Dis. 2003;16(4):389-95. Erratum in: Cerebrovasc Dis. 2004;17(1):91-2.

PMID:
14584489
22.

Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.

Tsimberidou AM, Colburn DE, Welch MA, Cortes JE, Verstovsek S, O'Brien SM, Albitar M, Kantarjian HM, Giles FJ.

Cancer Chemother Pharmacol. 2003 Sep;52(3):229-34. Epub 2003 May 29.

PMID:
12783207
23.

Skin infiltration with chronic lymphocytic leukemia is consistent with a good prognosis.

Colburn DE, Welch MA, Giles FJ.

Hematology. 2002 Jun;7(3):187-8.

PMID:
12243983
24.

What genetic testing can tell you about breast cancer risk.

Welch MA.

JAAPA. 2001 Mar;14(3):50-2, 57-8, 61. No abstract available.

PMID:
11523186
25.

Cocaine decreases cell survival and inhibits neurite extension of rat locus coeruleus neurons.

Snow DM, Smith JD, Booze RM, Welch MA, Mactutus CF.

Neurotoxicol Teratol. 2001 May-Jun;23(3):225-34.

PMID:
11418264
26.

Behavioral sensitization following repeated intravenous nicotine administration: gender differences and gonadal hormones.

Booze RM, Welch MA, Wood ML, Billings KA, Apple SR, Mactutus CF.

Pharmacol Biochem Behav. 1999 Dec;64(4):827-39.

PMID:
10593207
27.

Estrous cyclicity and behavioral sensitization in female rats following repeated intravenous cocaine administration.

Booze RM, Wood ML, Welch MA, Berry S, Mactutus CF.

Pharmacol Biochem Behav. 1999 Nov;64(3):605-10.

PMID:
10548278
28.
29.
30.

Reduction of lower extremity clinical abnormalities in patients with non-insulin-dependent diabetes mellitus. A randomized, controlled trial.

Litzelman DK, Slemenda CW, Langefeld CD, Hays LM, Welch MA, Bild DE, Ford ES, Vinicor F.

Ann Intern Med. 1993 Jul 1;119(1):36-41.

PMID:
8498761
31.

Lack of significant changes in nutrition-related parameters with tumor necrosis factor treatment of cancer.

Hurley RS, O'Dorisio TM, Rinehart JJ, Welch MA, Geraghty ME, Nahikian-Nelms M, Kinney P, Rice RR.

Nutr Cancer. 1993;19(3):253-61.

PMID:
8346074
32.

The effect of exercise training on body weight and peptide hormone patterns in normal weight college-age men.

Hurley RS, Bossetti BM, O'Dorisio TM, Tenison EB, Welch MA, Rice RR.

J Sports Med Phys Fitness. 1991 Mar;31(1):52-6.

PMID:
1861484
33.

The response of serum growth hormone and prolactin to training in weight-maintaining healthy males.

Hurley RS, Bossetti BM, O'Dorisio TM, Welch MA, Rice RR, Tenison EB, Wasson CJ, Malarkey WB.

J Sports Med Phys Fitness. 1990 Mar;30(1):45-8.

PMID:
2366534
34.

Platelet alpha granule secretion in cerebral ischemia: effect of short and long term low dose aspirin treatment.

D'Andrea G, Joseph R, Cananzi AR, Ferro-Milone F, Grunfeld S, Toldo M, Welch MA.

Funct Neurol. 1988 Apr-Jun;3(2):179-85.

PMID:
2456969
35.

The IPPB trial.

Shapiro BJ, Welch MA Jr, Mercurio P.

Ann Intern Med. 1984 Mar;100(3):457-8. No abstract available.

PMID:
6364913
36.

IPPB, SMI, gloves: good or bad?

Welch MA Jr.

Chest. 1981 May;79(5):615-6. No abstract available.

PMID:
7014126
37.

Methods of intermittent positive pressure breathing.

Welch MA Jr, Shapiro BJ, Mercurio P, Wagner W, Hirayama G.

Chest. 1980 Sep;78(3):463-7.

PMID:
6998663
38.

Intermittent positive-pressure breathing in asthma.

Welch MA Jr.

Chest. 1978 Mar;73(3):438-9. No abstract available.

PMID:
344010
39.

Sustained maximal inspiration and IPPB--proper evaluation in postoperative patients.

Welch MA Jr, Hasbrouck BU.

Respir Care. 1977 Nov;22(11):1188-91, 1193. No abstract available.

PMID:
10325141

Supplemental Content

Loading ...
Support Center